Epigenic Therapeutics, a Shanghai, China-based biotechnology company, raised $20M in Series Angel and Pre-A funding.
Backers included Morningside Venture Capital, Kingray Capital, Trinity Innovation Fund, TigerYeah Capital and FountainBridge Capital.
The company intends to use the funds to validate advances of its proprietary epigenetic editing in non-human primates, expand expertise and capabilities, and sponsor early-stage clinical investigations.
Led by CEO Bob Zhang, Epigenic Therapeutics is a biotechnology company dedicated to developing gene editing therapy utilizing regulation of epigenetic genome for a variety of diseases. The company’s proprietary technology platform employs its own artificial intelligence (AI) algorithms to explore and obtain an optimized CRISPR-Cas component to regulate target gene(s) or govern the expression of one or multiple gene(s) at once without changing the sequence of the DNA. Among peer technologies, the platform is capable to overcome the potential risk rising from DNA cleavage including but not limited to off-target effect, short half-life and challenging patient compliance issues. Combing a patented lipid nanoparticle (LNP) medicine delivery system, the platform has been proven to precisely and efficiently deliver medicine to target cells and tissues ex vivo and in vivo in ocular, neurodegeneration, metabolic, and rare disease models.